Ionis Pharmaceuticals EVP Eric Swayze sells shares worth $45,277

CARLSBAD, CA—Eric Swayze, Executive Vice President of Research at Ionis Pharmaceuticals Inc. (NASDAQ:), recently sold a portion of his holdings in the company. According to a filing with the Securities and Exchange Commission, Swayze sold 1,194 shares of Ionis common stock on November 12, 2024, at a weighted average price of $37.921 per share. This transaction, executed under a prearranged trading plan, brought in a total of $45,277.

Following this sale, Swayze retains direct ownership of 33,713 shares in the company. Additionally, he indirectly holds 157 shares through his son. The sales were part of a Rule 10b5-1 Trading Plan, which allows company insiders to sell a predetermined number of shares at a predetermined time, helping them avoid potential accusations of insider trading.

In other recent news, Ionis Pharmaceuticals, Inc. announced its third-quarter financial results for 2024, underlining the significance of non-GAAP financial results. The company believes these non-GAAP measures offer a more accurate reflection of their business operations and management. The earnings call was attended by Ionis' top executives, including CEO Brett Monia, who participated in a Q&A session to elaborate on the financial details.

The company did not report any financial misses or shortfalls in the third-quarter results. In addition, Ionis has not highlighted any specific bearish aspects but indicated confidence in their operational management and long-term prospects, as evidenced by their preference for non-GAAP financials.

These recent developments reflect Ionis' commitment to transparency and comprehensive review of their operations and strategy. To further support investors' understanding of the financials, the company has made available the presentation slides accompanying the call on the Ionis website.

InvestingPro Insights

As Eric Swayze reduces his stake in Ionis Pharmaceuticals, investors may want to consider additional financial metrics and expert insights to gain a more comprehensive view of the company's current position.

According to InvestingPro data, Ionis Pharmaceuticals has a market capitalization of $5.84 billion and is trading near its 52-week low. This could potentially signal an opportunity for investors, but it's crucial to examine the underlying fundamentals.

One InvestingPro Tip highlights that Ionis operates with a moderate level of debt, which may provide some financial flexibility. However, another tip indicates that the company suffers from weak gross profit margins, which is reflected in the reported gross profit margin of -14.31% for the last twelve months as of Q3 2023.

Despite these challenges, Ionis has shown strong revenue growth of 30.57% over the same period, reaching $803.07 million. This growth trajectory is encouraging, although analysts anticipate a sales decline in the current year, according to another InvestingPro Tip.

For investors seeking a more detailed analysis, InvestingPro offers 8 additional tips for Ionis Pharmaceuticals, providing a deeper understanding of the company's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.